pharma · Respiratory Syncytial Virus Infections · Asthma
MedImmune
MedImmune is a pharma organization headquartered in EU. Primary therapeutic focus areas include Respiratory Syncytial Virus Infections, Asthma, Influenza, Stage III Non-small Cell Lung Cancer, Chronic Obstructive Pulmona
Gaithersburg, USA HQ
1987 Founded
896 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Gaithersburg, USA
- Founded
- 1987
- Employees
- 896
- Programs
- 9
- Drugs
- 7
- Patents
- 0
Durvalumab + Oleclumab
Phase 2 · small molecule · Stage III Non-small Cell Lung Cancer
Durvalumab + Oleclumab for Stage III Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at MedImmune with 1 ClinicalTrials.gov record(s).
Internal code D9108C00001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- MedImmune
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Stage III Non-small Cell Lung Cancer
- Status
- completed
- Trials
- 1